share_log

Expert Ratings For Beam Therapeutics

Benzinga ·  Apr 23 14:00

In the latest quarter, 5 analysts provided ratings for Beam Therapeutics (NASDAQ:BEAM), showcasing a mix of bullish and bearish perspectives.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings03200
Last 30D01000
1M Ago01000
2M Ago00200
3M Ago01000

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $46.2, a high estimate of $57.00, and a low estimate of $35.00. This current average reflects an increase of 52.32% from the previous average price target of $30.33.

price target chart

Understanding Analyst Ratings: A Comprehensive Breakdown

The standing of Beam Therapeutics among financial...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment